Open AccessBack Cover: Therapeutic antibodies under development for SARS‐CoV‐2 (View 2/2022)
Author(s) -
Ma Zetong,
Zhu MengMei,
Zhang Shuyi,
Qian Kewen,
Wang Chuqi,
Fu Wenyan,
Lei Changhai,
Hu Shi
Publication year - 2022
Publication title -
view
Language(s) - English
Resource type - Journals
eISSN - 2688-268X
pISSN - 2688-3988
DOI - 10.1002/viw2.210
Subject(s) - antibody , covid-19 , epitope , virology , virus , antibody therapy , immune system , medicine , immunology , monoclonal antibody , disease , infectious disease (medical specialty)
Research on antibody therapy for SARS‐COV‐2 is in the ascendant, including single antibody therapy and multiple antibody combinations. The multi‐drug combination is also called an antibody cocktail, which relies on different antibodies to target different epitopes so it can avoid immune escape caused by mutations in a better way and achieve a better curative effect. In article number 20200178, Shi Hu and co‐workers have portrayed antibody cocktails as a kind of cocktails which is a mixture of different liqueurs in different colors. As the last drop of liquid is added, a cocktail specially tuned to hit the virus will be finished.